Related references
Note: Only part of the references are listed.Humanized anti-CD19 chimeric antigen receptor-T cell therapy is safe and effective in lymphoma and leukemia patients with chronic and resolved hepatitis B virus infection
Rui Cui et al.
HEMATOLOGICAL ONCOLOGY (2021)
Moderate Risk of Hepatitis B Virus Reactivation in HBsAg-/HBcAb+ Carriers Receiving Rituximab for Rheumatoid Arthritis
Meng Hsuan Kuo et al.
SCIENTIFIC REPORTS (2020)
Risk of hepatitis B reactivation is controllable in patients with B-cell lymphoma receiving anti-CD19 CAR T cell therapy
Wei Liu et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Chimeric antigen receptor T-cell therapy: a promising treatment modality for relapsed/refractory mantle cell lymphoma
Ping Li et al.
FRONTIERS OF MEDICINE (2020)
Different sites of extranodal involvement may affect the survival of patients with relapsed or refractory non-Hodgkin lymphoma after chimeric antigen receptor T cell therapy
Lili Zhou et al.
FRONTIERS OF MEDICINE (2020)
Risk of HBV reactivation post CD19-CAR-T cell therapy in DLBCL patients with concomitant chronic HBV infection
Chunmei Yang et al.
LEUKEMIA (2020)
Safety and efficacy of CAR-T cell targeting BCMA in patients with multiple myeloma coinfected with chronic hepatitis B virus
Lu Han et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Safety of CAR T-cell therapy in patients with B-cell lymphoma and chronic hepatitis B or C virus infection
Paolo Strati et al.
BLOOD (2019)
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
Noopur Raje et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Severe early hepatitis B reactivation in a patient receiving anti-CD19 and anti-CD22 CAR T cells for the treatment of diffuse large B-cell lymphoma
Jia Wei et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
Daniel W. Lee et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial
Frederick L. Locke et al.
LANCET ONCOLOGY (2019)
Fulminant Liver Failure due to Hepatitis B Reactivation During Treatment With Tocilizumab
Milan J. Sonneveld et al.
ACG CASE REPORTS JOURNAL (2019)
Hepatitis B virus and risk of non-Hodgkin lymphoma: An updated meta-analysis of 58 studies
M. Li et al.
JOURNAL OF VIRAL HEPATITIS (2018)
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Jae H. Park et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Prevention of Hepatitis B reactivation in the setting of immunosuppression
Venessa Pattullo
CLINICAL AND MOLECULAR HEPATOLOGY (2016)
Monitoring of Hepatitis B Virus (HBV) DNA and Risk of HBV Reactivation in B-Cell Lymphoma: A Prospective Observational Study
Shigeru Kusumoto et al.
CLINICAL INFECTIOUS DISEASES (2015)
American Gastroenterological Association Institute Technical Review on Prevention and Treatment of Hepatitis B Virus Reactivation During Immunosuppressive Drug Therapy
Robert P. Perrillo et al.
GASTROENTEROLOGY (2015)
Hepatitis B virus reactivation with a rituximab-containing regimen
Yutaka Tsutsumi et al.
WORLD JOURNAL OF HEPATOLOGY (2015)
Hepatitis B Reactivation in Patients With Previous Hepatitis B Virus Exposure Undergoing Rituximab-Containing Chemotherapy for Lymphoma: A Prospective Study
Wai-Kay Seto et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Randomized Controlled Trial of Entecavir Prophylaxis for Rituximab-Associated Hepatitis B Virus Reactivation in Patients With Lymphoma and Resolved Hepatitis B
Yi-Hsiang Huang et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Hepatitis B virus reactivation with rituximab-containing regimen
Yutaka Tsutsumi et al.
WORLD JOURNAL OF HEPATOLOGY (2013)
Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports
A. M. Evens et al.
ANNALS OF ONCOLOGY (2011)
Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma
AL Cheng et al.
HEPATOLOGY (2003)
Share Paper
